Modulation of hypovitaminosis D-induced islet dysfunction and insulin resistance through direct suppression of the pancreatic islet renin-angiotensin system in mice

Diabetologia

Volumn 56, Issue 3, 2013, Pages 553-562

  Cheng, Q ^a   Boucher, B J ^b   Leung, P S ^a  

^a Chinese University of Hong Kong   (Hong Kong)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Glucose homeostasis; Insulin resistance; Pancreatic islets; Renin inhibitor; Renin angiotensin system; Type 2 diabetes; Vitamin D

Indexed keywords

ALISKIREN; CALCIFEDIOL; CALCITRIOL; CALCIUM; INSULIN; PARATHYROID HORMONE; RECEPTOR; RENIN; RENIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; VITAMIN D DEFICIENCY;

ANIMALS; BLOTTING, WESTERN; CALCIUM; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; PARATHYROID HORMONE; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 84878344721     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2801-0     Document Type: Article

References (50)

1. Boucher BJ (2011) Vitamin D insufficiency and diabetes risks. Curr Drug Targets 12:61-87
2. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ (1995) Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 38:1239-1245
3. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ (2008) Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 57:2619-2625
4. Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820-825
5. Kayaniyil S, Retnakaran R, Harris SB et al (2011) Prospective associations of vitamin D with beta-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes 60:2947-2953
6. Vaidya A, Williams JS (2012) The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 61:450-458
7. Vaidya A, Sun B, Forman JP et al (2011) The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clin Endocrinol (Oxf) 74:783-790
8. Ogunkolade BW, Boucher BJ, Prahl JM et al (2002) Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 51:2294-2300
9. Norman AW, Frankel JB, Heldt AM, Grodsky GM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823-825
10. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG (2003) Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 17:509-511
11. Labriji-Mestaghanmi H, Billaudel B, Garnier PE, Malaisse WJ, Sutter BC (1988) Vitamin D and pancreatic islet function. I. Time course for changes in insulin secretion and content during vitamin D deprivation and repletion. J Endocrinol Invest 11:577-584
12. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr (2005) Angiotensin- converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821-826
13. Lau T, Carlsson PO, Leung PS (2004) Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47:240-248
14. Cheng Q, Law PK, de Gasparo M, Leung PS (2008) Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo] acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl] methyl]-L- valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 327:683-691
15. Chu KY, Lau T, Carlsson PO, Leung PS (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55:367-374
16. Chu KY, Leung PS (2007) Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young type 2 diabetic mice. Antioxid Redox Signal 9:869-878
17. Gerstein H, Yusuf S, Holman R, Bosch J, Pogue J (2004) Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 47:1519-1527
18. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J (2004) Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90:387-392
19. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238
20. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D (2008) Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74:170-179
21. Bodyak N, Ayus JC, Achinger S et al (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104:16810-16815
22. Kimura Y, Kawamura M, Owada M et al (1999) Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med 38:31-35
23. Tomaschitz A, Pilz S, Ritz E et al (2010) Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 411:1354-1360
24. Vaidya A, Forman JP, Hopkins PN, Seely EW, Williams JS (2011) 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 12:311-319
25. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105:15896-15901
26. Cheng Q, Li YC, Boucher BJ, Leung PS (2011) A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia 54:2077-2081
27. Morioka T, Asilmaz E, Hu J et al (2007) Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 117:2860-2868
28. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA (2010) Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 119:239-250
29. Muscogiuri G, Sorice GP, Prioletta A et al (2010) 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obes (Silver Spring) 18:1906-1910
30. Jorde R, Figenschau Y (2009) Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 48:349-354
31. Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562
32. Kalupahana NS, Moustaid-Moussa N (2012) The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 13:136-149
33. Ogihara T, Asano T, Ando K et al (2002) Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40:872-879
34. Lastra G, Habibi J, Whaley-Connell AT et al (2009) Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 150:2561-2568
35. Chu KY, Cheng Q, Chen C et al (2010) Angiotensin II exerts glucose-dependent effects on Kv currents in mouse pancreatic beta-cells via angiotensin II type 2 receptors. Am J Physiol Cell Physiol 298:C313-C323
36. Levin A, Bakris GL, Molitch M et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31-38
37. Sigmund CD (2002) Regulation of renin expression and blood pressure by vitamin D(3). J Clin Invest 110:155-156
38. Forman JP, Williams JS, Fisher ND (2010) Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55:1283-1288
39. Kitamura T, Nakae J, Kitamura Y et al (2002) The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110:1839-1847
40. Boquist L, Hellman B, Lernmark A, Taljedal IB (1974) Influence of the mutation «diabetes» on insulin release and islet morphology in mice of different genetic backgrounds. J Cell Biol 62:77-89
41. Kottgen A, Hwang SJ, Rampersaud E et al (2008) TCF7L2 variants associate with CKD progression and renal function in population-based cohorts. J Am Soc Nephrol 19:1989-1999
42. da Silva XG, Loder MK, McDonald A et al (2009) TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 58:894-905
43. Pessin JE, Saltiel AR (2000) Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165-169
44. Hennige AM, Ozcan U, Okada T et al (2005) Alterations in growth and apoptosis of insulin receptor substrate-1-deficient beta-cells. Am J Physiol Endocrinol Metab 289:E337-E346
45. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK (2005) Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 25:1142-1147
46. Hashimoto N, Kido Y, Uchida T et al (2006) Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 38:589-593
47. Saad MJ, Hartmann LG, de Carvalho DS, Galoro CA, Brenelli SL, Carvalho CR (1995) Effect of glucagon on insulin receptor substrate-1 (IRS-1) phosphorylation and association with phosphatidylinositol 3-kinase (PI 3-kinase). FEBS Lett 370:131-134
48. Thorens B (2011) Of fat, beta cells, and diabetes. Cell Metab 14:439-440
49. www.fda.gov/drugs/drugsafety/ucm300889.htm, last accessed, 8 November, 2012
50. Parving HH, Brenner BM, McMurray JJ et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. doi: 10.1056/NEJMoa1208799